Nucleic Acid-based Therapeutics Market Research Report- Forecast to 2032

Nucleic Acid-based Therapeutics Market Research Report Information By Technology (Anti-Sense and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers), By Applications (Monogenetic disorders, Thalassemia, Sickle cell anemia, Hemophilia, Cystic Fibrosis etc., Multi-genetic disorders, Cancer, Diabetes, Neurodegenerative Diseases, Cardiovascular Diseases, etc.), By End Users (Hospitals, and Academic & Research Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World

ID: MRFR/Pharma/2192-HCR | 75 Pages | Author: Kinjoll Dey | March 2024         

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Nucleic Acid-based Therapeutics Market, by Technology

5.1 Introduction

5.1.1 Anti-Sense and Anti-Gene

5.1.2 Short Inhibitory Sequences

5.1.3 Gene Transfer Therapy

5.1.4 Nucleoside Analogs

5.1.5 Ribozymes

5.1.6 Aptamers

5.1.7 Others

6 Global Nucleic Acid-based Therapeutics Market, by Applications

6.1 Introduction

6.1.1 Monogenetic disorders

6.1.2 Multi-genetic disorders

7 Global Nucleic Acid-based Therapeutics Market, by End User

7.1 Introduction

7.1.1 Hospitals

7.1.3 Academic & Research Institutes

7.1.6 Others

8 Global Nucleic Acid-based Therapeutics Market, by Regions

8.1 Introduction

8.1.1 Americas

8.1.1.1 North America

8.1.1.2 South America

8.1.2 Europe

8.1.2.1 Germany

8.1.2.2 France

8.1.2.3 UK

8.1.2.4 Italy

8.1.2.5 Spain

8.1.2.6 Rest of Europe

8.1.3 Asia Pacific

8.1.3.1 Japan

8.1.3.2 China

8.1.3.3 India

8.1.3.4 Republic of Korea

8.1.3.5 Rest of Asia Pacific

8.1.4 Middle East & Africa

9 Company Landscape

9.1 Introduction

9.1.1 Mergers Acquisitions

9.1.2 Collaborations

9.1.3 Release/New Product Launches

9.1.4 Other (Expansion, Updates, Partnership)

10 Company Profile

10.1 Wave Life Sciences Ltd., Copernicus Therapeutics Inc.

10.1.1 Company Overview

10.1.2 Product/Business Segment Overview

10.1.3 Financials

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Imugene

10.2.1 Overview

10.2.2 Product/Business Segment Overview

10.2.3 Financials

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Caperna

10.3.1 Overview

10.3.2 Product/Business Segment Overview

10.3.3 Financials

10.3.4 Key Developments

10.3.5 SWOT Analysis

10.4 Phylogica

10.4.1 Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financials

10.4.4 Key Developments

10.4.5 SWOT Analysis

10.5 Protagonist Therapeutics

10.5.1 Overview

10.5.2 Product/Business Segment Overview

10.5.3 Financials

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Benitec Biopharma

10.6.1 Overview

10.6.2 Product/Business Segment Overview

10.6.3 Financials

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 EGEN (Expression Genetics)

10.7.1 Overview

10.7.2 Product/Business Segment Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 BioMedica (Oxford BioMedica)

10.8.1 Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.9 Transgene

10.9.1 Overview

10.9.2 Product/Business Segment Overview

10.9.3 Financials

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.10 Others

11 Appendix

List of Tables

TABLE 1 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, 2023-2030 (USD MILLION)

TABLE 2 GLOBAL NUCLEIC ACID- BASED THERAPEUTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)

TABLE 3 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY APPLICATIONS, 2023-2030 (USD MILLION)

TABLE 4 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 5 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY REGION, 2023-2030 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY TECHNOLOGY

FIGURE 4 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY APPLICATIONS

FIGURE 5 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY END USER

FIGURE 6 GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET, BY REGION

FIGURE 7 GLOBAL NUCLEIC ACID - BASED THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

Nucleic Acid-based Therapeutics Market Segmentation


Nucleic Acid-based Therapeutics Technology Outlook (USD Billion, 2019-2030)




  • Anti-Sense and Anti-Gene




  • Short Inhibitory Sequences




  • Gene Transfer Therapy




  • Nucleoside Analogs




  • Ribozymes




  • Aptamers




Nucleic Acid-based Therapeutics Application Outlook (USD Billion, 2019-2030)




  • Monogenetic disorders




  • Thalassemia




  • Sickle cell anemia




  • Hemophilia




  • Cystic Fibrosis etc.




  • Multi-genetic disorders




  • Cancer




  • Diabetes




  • Neurodegenerative Diseases




  • cardiovascular Diseases etc.




Nucleic Acid-based Therapeutics End Users Outlook (USD Billion, 2019-2030)




  • Hospitals




  • Academic & Research Institutes




Nucleic Acid-based Therapeutics Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • North America Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc.






    • North America Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • US Outlook (USD Billion, 2019-2030)




    • US Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • US Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc






    • US Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • CANADA Outlook (USD Billion, 2019-2030)




    • CANADA Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • CANADA Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc.






    • CANADA Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Europe Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc.






    • Europe Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Germany Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc.






    • Germany Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • France Outlook (USD Billion, 2019-2030)




    • France Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • France Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • France Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • UK Outlook (USD Billion, 2019-2030)




    • UK Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • UK Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc.






    • UK Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • ITALY Outlook (USD Billion, 2019-2030)




    • ITALY Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • ITALY Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • cardiovascular Diseases etc.






    • ITALY Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • SPAIN Outlook (USD Billion, 2019-2030)




    • Spain Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Spain Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Spain Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Rest of Europe Outlook (USD Billion, 2019-2030)




    • Rest of Europe Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • REST OF EUROPE Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • REST OF EUROPE Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Asia-Pacific Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Asia-Pacific Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • China Outlook (USD Billion, 2019-2030)




    • China Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • China Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • China Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Japan Nucleic Acid-based Therapeutics by Technology




      • Metal




      • Polymer




      • Others






    • Japan Nucleic Acid-based Therapeutics by Applications




      • Minimally Invasive Spine Surgery




      • Open Spine Surgery






    • Japan Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • India Outlook (USD Billion, 2019-2030)




    • India Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • India Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • India Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Australia Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Australia Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Rest of Asia-Pacific Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Rest of Asia-Pacific Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes








  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Rest of the World Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Rest of the World Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Middle East Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Middle East Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Africa Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Africa Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Nucleic Acid-based Therapeutics by Technology




      • Anti-Sense and Anti-Gene




      • Short Inhibitory Sequences




      • Gene Transfer Therapy




      • Nucleoside Analogs




      • Ribozymes




      • Aptamers






    • Latin America Nucleic Acid-based Therapeutics by Applications




      • Monogenetic disorders




      • Thalassemia




      • Sickle cell anemia




      • Hemophilia




      • Cystic Fibrosis etc.




      • Multi-genetic disorders




      • Cancer




      • Diabetes




      • Neurodegenerative Diseases




      • Cardiovascular Diseases etc.






    • Latin America Nucleic Acid-based Therapeutics by End Users




      • Hospitals




      • Academic & Research Institutes







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid